Physician profile
Lara Le
NPI 1043239841
$6,766.85
in general payments reported to CMS, 2019-2025
33 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $271 · 2021: $789 · 2022: $1,291 · 2023: $1,146 · 2024: $808 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002 · Travel and Lodging: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.52 |
| Travel and Lodging | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,460.70 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $917.62 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $692.30 | 2019-2025 | Prolia, Evenity, Repatha |
| Abbvie INC. | $468.38 | 2021-2024 | |
| Pfizer INC. | $321.61 | 2019-2024 | |
| Lilly USA, LLC | $307.26 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $285.74 | 2019-2025 | |
| Biotronik INC. | $277.97 | 2021-2023 | Biomonitor |
| Janssen Pharmaceuticals, INC | $259.00 | 2019 | |
| Abbott Laboratories | $193.18 | 2023 | Freestyle Libre 3, Octrode |
| Otsuka America Pharmaceutical, INC. | $166.96 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $150.01 | 2019-2025 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $145.65 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.20 | 2020-2022 | |
| Eisai INC. | $123.91 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $123.91 | 2024 | Veozah |
| Alkermes, INC. | $112.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.32 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $101.42 | 2019-2025 | Enflonsia, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $86.67 | 2020-2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $50.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $46.50 | 2019 | |
| Sumitomo Pharma America, INC. | $32.08 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $28.82 | 2024 | Zoryve |
| Gilead Sciences, INC. | $27.95 | 2025 | |
| Sanofi Pasteur INC. | $25.46 | 2019 | |
| Idorsia Pharmaceuticals US INC | $24.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.12 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.61 | 2025 | Caplyta |
| Irhythm Technologies, INC. | $14.55 | 2024 | Zio Xt Patch, Zio Monitor |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.12 | 2022 | |
| Phadia US INC. | $13.44 | 2024 | Immunocap |
| Biowound Solutions, INC. | $9.57 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.